Recent Study Finds Digital IDs Not Ready to Replace Physical Documents — Yet
11.6.2024 09:30:00 EEST | Business Wire | Press release
As innovative digital verification methods continue to emerge, the debate around their reliability and effectiveness is heating up. Yet, a recent study “The New Imperative: Digital IDs” commissioned by Regula reveals the lasting importance of physical identity documents. Despite digital advances, a high percentage of organizations worldwide still depend on physical documents for verification.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610221791/en/
According to Regula's study, digital IDs will not replace physical documents in the near future. The majority of companies globally rely on automation and biometrics for remote identity verification. (Graphic: Business Wire)
Current state. Companies employ various methods for identity verification, as shown in a Forrester Consulting study commissioned by Regula. 46% of respondents verify documents manually, even in remote scenarios involving video interviews or passport scan submission. Some companies have automated this process (53%) or switched to more secure forms of user authentication such as biometrics (54%) or multi-factor authentication (49%). A significant number of companies (44%) use third-party services that also often count on physical documents for thorough identity checks.
The Forrester Consulting study suggests that, while innovative digital verification methods are evolving, physical identity documents remain indispensable, ensuring reliable and trustworthy identity verification across various regulatory environments.
The reliance on physical documents is more pronounced in industries where security demands are stringent, such as Aviation (63%) and Finance (44%). Organizations from countries with rigid regulatory frameworks, including the US (50%) and Germany (49%), also stay true to manual checks.
Barriers to widespread Digital ID adoption. One of the obstacles on the road to broad adoption of the Digital ID concept is the lack of a general legislative framework for this form of identity proofing. 74% of respondents underscore the necessity for global digital ID standards and legislation to ensure interoperability of such IDs across borders.
However, with varied regional perspectives on identity and privacy (71%) and the technological disparity between countries (70%)—which are also named among the concerns—agreeing on these standards will be challenging. To address these difficulties, the situation requires collaborative innovation from authorities, businesses, and players in the identity verification (IDV) market.
The unified approach will become a pivot for establishing a consistently high reliability rate for Digital ID and contributing to the evolution of the IDV market. Sooner or later, this process will begin, since 72% of surveyed stakeholders believe the integration of digital IDs helps develop a robust global digital economy.
“Digital ID represents a significant change in how we approach identity verification, offering a brand-new dimension to our existing frameworks. However, the introduction of Digital ID as it now stands will not lead to the disruption of the IDV market. There are many signals indicating the need for long-term support of current identification types. While countries can adopt the new approach at their own pace domestically, a global shift to Digital IDs must be ubiquitous. This transition is hampered by various obstacles associated with political and economic issues, as well as a lack of universal public recognition of the technology. Eventually, obtaining Digital IDs will likely require presenting physical passports or ID cards, at least during the initial issuance stage. Even after the appearance of a complete ICAO standard for Digital ID, its worldwide adoption and the development of such a system will take time, and may involve considerable costs. Until this happens, we are just beginning to research the potential of this novelty,” said Ihar Kliashchou, Chief Technology Officer at Regula.
You can download the complete study with all the details for free here.
More on the topic:
- 42% of companies globally are ready to implement Digital ID.
- EU Digital Identity Wallet: Exploring Its Current Potential.
- 9 Identity Verification Trends Shaping 2024 for Forward-Thinking Businesses.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed.
Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610221791/en/
Contact information
Kristina – ks@regulaforensics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
